View Cart  

Novo Nordisk Halts Hemophilia Drug’s Development, Three Others Remain

A A
Novo Nordisk has discontinued development of one of its four hemophilia drug candidates following data from a Phase IIIa trial that found anti-drug antibodies and further potential risks for hemophilia patients with inhibitors.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00